Navigation Links
University of Cincinnati leads first trial on steroid and CNI withdrawal post-transplant
Date:11/28/2012

CINCINNATIThe University of Cincinnati will lead a $5.2 million national trial studying removal of both corticosteroids and common immunosuppression treatments from the post-transplant drug regimen for kidney transplant patients.

The Belatacept Early Steroid withdrawal Trial (BEST) seeks to determine if a belatacept-based regimen for post-transplant patients can prevent organ rejection without the harmful side effects posed by corticosteroids and calcineurin inhibitor (CNI) immunosuppressants. Belatacept is a modified version of the drug abatacept, which is used to treat rheumatoid arthritis.

Led by principal investigator and director of UC's division of transplantation E. Steve Woodle, MD, the $5.2 million trial will be carried out at four other transplant centers across the country: University of Wisconsin, University of Minnesota, California Pacific Medical Center and the Christ Hospital in Cincinnati.

The BEST study is the first large, multicenter trial to remove both corticosteroids and CNIs from a patient's drug regimen after kidney transplantation. Both drugs place patients at an increased risk of cardiovascular disease, high blood pressure, high cholesterol and diabetes. Additionally, CNIs have shown toxicity to transplanted kidneys.

"Cardiovascular events like stroke and heart attacks are the top cause of death for both the general population and transplant patients," says Woodle, who also serves as William A. Altemeier Chair in the UC Department of Surgery. "We've previously demonstrated that early steroid withdrawal results in reduced rates of rejection and increased graft survival in transplant patients."

Rita Alloway, PharmD, research professor of medicine and director of transplant clinical research within the UC Department of Internal Medicine, will direct the coordinating center for the trial. She says belatacept was approved by the Food and Drug Administration in 2011 for prevention of rejection in kidney transplant patientsthe first FDA-approved drug to replace CNIs like tacrolimus and cyclosporine.

"This trial is a major step forward in immunosuppression because it provides a means to avoid many of the toxicities of the CNI drugs, particularly kidney toxicity, high blood pressure, and hyperlipidemia," says Alloway.

Adele Shields, PhD, associate research professor of surgery with clinical practice at the Christ Hospital, has specialized in quantitating the impact of long-term immunosuppression on cardiac risk factors and cardiac events.

"An important feature of the belatacept-based treatment regimen is that it provides an opportunity to greatly minimize cardiovascular risk in the long term," she says. "By avoiding both CNIs and corticosteroids, this trial provides an opportunity to substantially impact long-term patient survival following kidney transplantation."


'/>"/>

Contact: Kathryn Cosse
kathryn.cosse@uc.edu
513-558-0207
University of Cincinnati Academic Health Center
Source:Eurekalert

Related medicine news :

1. Thomas Jefferson University honoring Axel Ullrich with Lennox K. Black International Prize
2. University Hospitals & Philips Healthcare to showcase imaging technology at Cleveland Medical Mart
3. University of Tennessee study: Unexpected microbes fighting harmful greenhouse gas
4. Scientists at Mainz University identify inhibitor of myelin formation in the central nervous system
5. University of Pennsylvania Medicine receives National Institutes of Health grant to help local communities move forward after asbestos exposure
6. Allied Minds and The George Washington University partner to form LuxCath LLC
7. New era in metabolomics begins at University of Michigan
8. Umeå University hosts new World Health Organization Collaborating Centre
9. George Mason University researchers target breast cancer in 3 trials
10. Research prizes from the Carlsberg Foundation to researchers from University of Copenhagen
11. University of Houston India Studies Program presents Circuits of Empire: India as Metropole
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2020)... ... September 02, 2020 , ... RAM ... payers administering Medicare Advantage and Special Needs plans, is proud to support the ... Insurance Plans (AHIP). RAM is supporting the event as a sponsor and exhibitor ...
(Date:9/1/2020)... ... September 01, 2020 , ... Dr. ... training in aesthetic surgery of the face, breast, and body. In 2018, she ... premier boutique plastic surgery and aesthetic practice in Southwest Florida. Dr. Gill and ...
(Date:8/31/2020)... ... August 31, 2020 , ... Want to get moving, break up your routine, ... (CPARF) is thrilled to launch its fourth annual STEPtember campaign in the United States ... meets everyone wherever they are at this moment — encouraging people to move in ...
(Date:8/31/2020)... ... ... for Covid-19 “PTS” with Mediation & Hypnosis , At this very turbulent time in ... deep anxiety, immense stress, and right now are needing serious relief from a constant state ... planet are experiencing a great degree of emotional discomfort, be it fear or worrying about ...
(Date:8/28/2020)... ... August 28, 2020 , ... Ernst & Young ... named an Entrepreneur Of The Year® 2020 Florida Award finalist. Now in its ... ambitions deliver innovation, growth and prosperity as they build and sustain successful businesses ...
Breaking Medicine News(10 mins):
(Date:8/31/2020)... PHOENIX (PRWEB) , ... August 31, 2020 , ... ... Mobile Sanitizing and Disinfecting - a broad-spectrum sanitization, disinfection and deodorization provider ... company will offer door-to-door sanitizing and disinfecting services for businesses and residents throughout ...
(Date:8/28/2020)... ... August 28, 2020 , ... ... aesthetic beauty, bringing a unique perspective and approach. Armed with her qualifications from ... out to share her knowledge of the human body with the nation and ...
(Date:8/27/2020)... (PRWEB) , ... August 27, 2020 , ... Bleep LLC, ... player and sleep apnea patient, is the company’s new spokesperson. , “In my line ... field. So, when I found the Bleep DreamPort it was a Bleeping no brainer ...
Breaking Medicine Technology: